Product Images Sunitinib Malate

This appears to be data from a clinical trial comparing the effectiveness of a drug called Sunitinib versus a placebo in treating a certain condition. The drug group (Sunitinib) had 207 participants with a median time to tumor progression of 27.3 weeks, while the placebo group had 105 participants with a median time to tumor progression of 6.4 weeks. The hazard ratio was 0.33 with a 95% confidence interval of 0.23 to 0.47 and a p-value of less than 0.0001. The graph shows a probability of time to tumor progression over the course of the study for both groups.*

This is a statistical comparison of the efficacy of a drug called Sunitinb versus a placebo. It shows data for 309 subjects who were given Sunitinb and 306 subjects who were given a placebo. The median time of treatment was 6.8 years for Sunitinb. The data suggests that the hazard ratio for Sunitinb is 0.76 with a 85% confidence interval of 0.59–0.58 and a p-value of 0.03. The graphs show the number of subjects who survived at certain time intervals.*

This appears to be a statistical report of clinical trial results for a drug called "Sunitinib" compared to a placebo. There were 86 subjects in the Sunitinib group and 85 in the placebo group. The median survival time for subjects in the Sunitinib group was 10.2 months compared to 5.4 months in the placebo group. The hazard ratio was calculated to be 0.427 with 95% confidence interval between 0.271-0.673. The rest of the text seems to be a graph with the number of subjects over time, but it is not readable due to missing labels and formatting.*

Sunitinib Malate Capsules are a prescription medication for patients. The usual dosage and prescribing information are found in the accompanying material. It is important to keep this and all medication out of reach. The manufacturer is stated as Hyn| Worgariowm, WU 26805 USA.*

This is a prescription medicine called Sunitinib used to treat certain types of cancer. It comes in the form of capsules each containing 375 mg of the active ingredient known as sunitinib malate. The medication is only dispensed upon the prescription of a licensed healthcare provider. The accompanying package insert contains important information on dosage and administration. The medication should be kept out of the reach of children and stored in a controlled room. The drug is manufactured by Mylan in Puerto Rico.*

This is a description for a medication called "suntinib malate" that comes in a container with a child-resistant closure. The medication should be kept tightly closed and out of reach of children, and stored at 20-25°C (69-77°F). The packaging of this medication may contain 28 capsules. Dosage information can be found in the accompanying materials, and this medication requires a prescription from a pharmacist.*